1.24
price down icon5.34%   -0.07
after-market Handel nachbörslich: 1.29 0.05 +4.03%
loading
Schlusskurs vom Vortag:
$1.31
Offen:
$1.28
24-Stunden-Volumen:
97,800
Relative Volume:
0.45
Marktkapitalisierung:
$16.78M
Einnahmen:
$1.89M
Nettoeinkommen (Verlust:
$-17.92M
KGV:
-0.1854
EPS:
-6.69
Netto-Cashflow:
$-15.62M
1W Leistung:
-8.15%
1M Leistung:
-22.50%
6M Leistung:
-39.51%
1J Leistung:
+13.76%
1-Tages-Spanne:
Value
$1.235
$1.30
1-Wochen-Bereich:
Value
$1.235
$1.375
52-Wochen-Spanne:
Value
$0.7707
$6.40

Longeveron Inc Stock (LGVN) Company Profile

Name
Firmenname
Longeveron Inc
Name
Telefon
305-302-7158
Name
Adresse
1951 NW 7TH AVENUE, MIAMI
Name
Mitarbeiter
25
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
LGVN's Discussions on Twitter

Vergleichen Sie LGVN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LGVN
Longeveron Inc
1.24 20.26M 1.89M -17.92M -15.62M -6.69
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Longeveron Inc Stock (LGVN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-06 Eingeleitet ROTH MKM Buy

Longeveron Inc Aktie (LGVN) Neueste Nachrichten

pulisher
May 29, 2025

Here's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash Wisely - Yahoo Finance

May 29, 2025
pulisher
May 22, 2025

Q2 Earnings Estimate for Longeveron Issued By HC Wainwright - Defense World

May 22, 2025
pulisher
May 20, 2025

Longeveron Inc. to Explore Partnership Opportunities for Alzheimer’s Stem Cell Therapy Program at BIO International Convention - Nasdaq

May 20, 2025
pulisher
May 20, 2025

Longeveron® to Attend BIO International Convention 2025 - Yahoo Finance

May 20, 2025
pulisher
May 12, 2025

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient - GlobeNewswire

May 12, 2025
pulisher
May 12, 2025

Longeveron Inc. Named Top 40 Semifinalist in XPRIZE Healthspan Competition for Stem Cell Therapy Evaluation in Alzheimer’s Disease and HLHS - Nasdaq

May 12, 2025
pulisher
May 11, 2025

Longeveron (LGVN) Projected to Post Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 09, 2025

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update - BioSpace

May 09, 2025
pulisher
May 09, 2025

Longeveron Q1 2025 slides: promising clinical data amid financial headwinds By Investing.com - Investing.com India

May 09, 2025
pulisher
May 09, 2025

Longeveron Reports Q1 2025 Progress and Financials - TipRanks

May 09, 2025
pulisher
May 08, 2025

Earnings call transcript: Longeveron Reports Q1 2025 Results Amid Revenue Decline - Investing.com Canada

May 08, 2025
pulisher
May 07, 2025

Longeveron Inc (LGVN) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance

May 07, 2025
pulisher
May 03, 2025

Contineum Therapeutics (NASDAQ:CTNM) versus Longeveron (NASDAQ:LGVN) Financial Survey - Defense World

May 03, 2025
pulisher
May 02, 2025

Longeveron Earnings Preview: Latest Updates on Cellular Therapy Pipeline Coming May 8 - Stock Titan

May 02, 2025
pulisher
May 02, 2025

Longeveron Inc. to Report Q1 2025 Financial Results and Business Update on May 8 - Nasdaq

May 02, 2025
pulisher
May 02, 2025

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - The Manila Times

May 02, 2025
pulisher
May 01, 2025

Longeveron Re-approves Cash-to-Equity Program Strategy - TipRanks

May 01, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 22, 2025

Longeveron® Issues Letter to Shareholders Highlighting - GlobeNewswire

Apr 22, 2025
pulisher
Apr 22, 2025

FDA Green Lights Longeveron's Fast-Track Strategy: Key Trials Near Completion for $10B+ Markets - Stock Titan

Apr 22, 2025
pulisher
Apr 10, 2025

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update - Seeking Alpha

Apr 10, 2025
pulisher
Apr 03, 2025

Where Will Palantir Stock Be in 1 Year? - The Globe and Mail

Apr 03, 2025
pulisher
Mar 28, 2025

Longeveron Files $70 Million Mixed Shelf - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Longeveron Inc Files For Mixed Shelf Of Up To $70 MillionSEC Filing - MarketScreener

Mar 28, 2025
pulisher
Mar 23, 2025

Longeveron (NASDAQ:LGVN) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Pharma company behind Alzheimer’s treatment closer to FDA approval - The Business Journals

Mar 21, 2025
pulisher
Mar 20, 2025

FDA aligns with Longeveron on Alzheimer’s therapy trial By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

FDA aligns with Longeveron on Alzheimer’s therapy trial - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron announces outcome of Type B meeting with FDA on Lomecel-B - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

FDA Clears BLA Pathway for Longeveron's Alzheimer's Cell Therapy | LGVN Stock News - Stock Titan

Mar 20, 2025
pulisher
Mar 20, 2025

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire

Mar 20, 2025
pulisher
Mar 11, 2025

Laromestrocel shows promise in Alzheimer’s trial By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B(TM)) In Alzheimer'S Disease - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Laromestrocel shows promise in Alzheimer’s trial - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron announces publication of results of Phase 2a trial of Lomecel-B - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron Inc. Reports Positive Phase 2a Results for Laromestrocel (Lomecel-B™) in Mild Alzheimer’s Disease Treatment - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Game-Changing Alzheimer's Treatment: Longeveron's Drug Delivers Cognitive Improvements in Nature Study - StockTitan

Mar 11, 2025
pulisher
Mar 07, 2025

Q1 Earnings Forecast for Longeveron Issued By HC Wainwright - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Q1 Earnings Estimate for Longeveron Issued By Roth Capital - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Q1 Earnings Forecast for Longeveron Issued By Roth Capital - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

FY2025 EPS Estimates for Longeveron Reduced by Analyst - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript - MSN

Mar 06, 2025
pulisher
Mar 05, 2025

Longeveron® to Present at the 37th Annual Roth Conference - The Manila Times

Mar 05, 2025
pulisher
Mar 05, 2025

How Longeveron's Upcoming Roth Conference Appearance Could Spotlight Its Cellular Therapy Pipeline - StockTitan

Mar 05, 2025
pulisher
Mar 04, 2025

Longeveron Inc. Reports Strong 2024 Financial Growth - TipRanks

Mar 04, 2025

Finanzdaten der Longeveron Inc-Aktie (LGVN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):